Valuation: Nuvectra Corporation

Market Cap 1.7M 1.52M 1.39M 1.27M 2.37M 161M 2.42M 16.63M 6.7M 84.9M 6.38M 6.24M 268M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -47.73M -43.8M -39.84M -74.7M -5.06B -76.18M -523M -211M -2.67B -201M -196M -8.44B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 30/01/2019
Compliance Officer 51 31/12/2014
Director TitleAgeSince
Director/Board Member 67 29/02/2016
Director/Board Member 78 29/02/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
+3.28%+4.82%-11.22%+14.57% 184B
+2.54%+4.43%+9.74%+37.31% 118B
+4.35%-0.32%-14.80%+9.67% 111B
+1.41%+6.80%-41.04%+6.45% 94.58B
+1.18%+1.56%-1.69%+74.40% 63.13B
-5.48%-5.08%-1.24%+63.86% 55.66B
+0.48%+1.58%+12.51%-22.05% 53.9B
+20.00%+16.49%-8.12%+58.37% 43.42B
+2.23%+4.24%+2.48%-8.32% 34.68B
Average +3.01%+1.72%-5.93%+26.03% 75.84B
Weighted average by Cap. +3.00%+0.24%-8.18%+23.84%

Financials

2017 2018
Net sales 31.84M 28.42M 26.08M 23.73M 44.48M 3.01B 45.37M 312M 126M 1.59B 119M 117M 5.02B 48.83M 43.6M 40.01M 36.39M 68.23M 4.62B 69.59M 478M 193M 2.44B 183M 179M 7.71B
Net income -44.6M -39.82M -36.54M -33.24M -62.32M -4.22B -63.56M -436M -176M -2.23B -167M -164M -7.04B -48.13M -42.97M -39.43M -35.87M -67.25M -4.56B -68.59M -471M -190M -2.41B -181M -177M -7.6B
Net Debt -1.49M -1.33M -1.22M -1.11M -2.08M -141M -2.12M -14.58M -5.88M -74.45M -5.59M -5.47M -235M -55.16M -49.25M -45.19M -41.11M -77.07M -5.22B -78.61M -540M -218M -2.76B -207M -203M -8.71B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock